Portuguese 
English 
Spanish 
4 min of reading 
0 comments 
An American startup is using human brains donated after death to test experimental drugs, promising to accelerate research against neurodegenerative diseases and raising strong ethical doubts.
In a laboratory that seems to have come out of a horror movie, scientists from a United States startup are keeping biologically active human brains without bodies to test experimental drugs against devastating diseases. The technology is from Bexorg, a Connecticut company, and was described in a report by the magazine Science about human brains used in drug tests after death.
The scene is disturbing: organs removed from recently deceased people are connected to a machine that pumps a kind of artificial blood, bringing oxygen and nutrients into the brain tissues. The goal, according to the researchers, is not to “resurrect” anyone but to keep the brain functioning at a cellular level long enough to observe how it reacts to new treatments.
The procedure has reignited an explosive debate: to what extent can science go when it starts working with post-mortem human brains, still capable of responding to biological stimuli?
-
Tiny robots inspired by ants can build and demolish structures on their own in a Harvard experiment.
-
Mansion basement becomes archaeological site: engravings possibly made by enslaved people are found in a property over 260 years old in Ouro Preto
-
A 13-meter marine predator, larger than two articulated buses, spent decades in Texas museum collections right under the noses of paleontologists: now named Tylosaurus rex, it had serrated teeth capable of crushing skulls and dominated the oceans of North America 80 million years ago.
-
Australia transforms remnants of plastic bags, glass bottles, and printer cartridges into new roads; each kilometer of Reconophalt uses 200,000 bags, 63,000 bottles, toner from 4,500 cartridges, and 50 tons of repurposed pavement.
The laboratory that seems like science fiction, but is real
The central technology of Bexorg is called BrainEx. The system keeps essential parts of the brain functioning by circulating an artificial solution through the organ’s blood vessels, preserving molecular and metabolic activities for a few hours.
During this period, researchers apply experimental drugs and monitor, in real-time, how the brain cells, proteins, and structures react. According to the information released, the company has already conducted tests on more than 700 human brains.
After about 24 hours, the process is concluded. The brain is then divided into hundreds of parts for more detailed analyses, allowing scientists to understand if a substance reached the correct target, how long it remained active, and if it caused signs of side effects.
The promise: accelerate treatments against Alzheimer’s and Parkinson’s
Behind the frightening image, there is a powerful medical promise. Bexorg claims that this technology can help find treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases more quickly and accurately.
Today, many drugs are first tested on laboratory animals, such as rats and pigs. The problem is that an animal’s brain does not perfectly replicate the human brain. A substance may work in a rat and completely fail in a person.
With real human brains, scientists can observe reactions in tissues that carry decades of biological history, environmental exposure, medication use, and natural aging. This detail can be crucial for understanding diseases that primarily affect older people.
The most controversial point: could these brains regain consciousness?
The big question haunting the case is inevitable: could a brain kept functioning outside the body somehow regain consciousness?
The company denies this possibility. According to those responsible, the brains do not exhibit the coordinated electrical activity necessary for thoughts, memories, pain, or conscious experiences. To further reduce any risk, the fluid used in the process contains propofol, an anesthetic capable of suppressing brain electrical activity.
Even so, bioethics experts warn that the technology opens up a completely new territory. The fear is not only scientific but moral: if an isolated human brain reached some minimal level of perception, medicine would face an unprecedented ethical problem.
Why do scientists defend such a macabre technique?
Despite the visual and emotional impact, researchers argue that the method may be more useful — and even more ethical — than relying solely on animal testing.
The logic is simple: if the goal is to develop drugs for the human brain, it makes sense to observe the drug’s behavior in a real human brain, and not just in lab-grown cells or animal models.
Additionally, the technology could prevent years of useless research and save millions in the development of drugs that often fail in advanced stages of clinical trials.
Biohaven already targets tests with data obtained from human brains
One of the most striking pieces of information is that the pharmaceutical company Biohaven is preparing to move forward with a clinical trial of a drug developed with the support of data obtained through Bexorg’s platform.
The treatment targets the loss of cellular energy in brains affected by neurodegenerative diseases. In another cited case, a potential treatment for Parkinson’s did not work in mice but showed a response in isolated human brains with a much lower dose than initially expected.
This type of result is precisely what makes the technology so attractive to the pharmaceutical industry.
A medical leap or a dangerous frontier?
The case of Bexorg places science at an uncomfortable frontier. On one side, there is the real chance of accelerating discoveries against diseases that destroy memories, movements, and identities. On the other, there is the fear that humanity is opening doors it does not yet know how to control.
For now, the company claims that their brains are not “alive” in the human sense of the word. They do not think, feel, or remember. But they remain active enough to respond to drugs.
And it is precisely this gray area — between definitive death and biological activity — that transforms Bexorg’s laboratory into one of the most disturbing and fascinating experiments of modern medicine.
Be the first to react!